These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35236391)

  • 21. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
    JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
    Raghu G; Brown KK; Collard HR; Cottin V; Gibson KF; Kaner RJ; Lederer DJ; Martinez FJ; Noble PW; Song JW; Wells AU; Whelan TP; Wuyts W; Moreau E; Patterson SD; Smith V; Bayly S; Chien JW; Gong Q; Zhang JJ; O'Riordan TG
    Lancet Respir Med; 2017 Jan; 5(1):22-32. PubMed ID: 27939076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Traditional Chinese medicine in the treatment of idiopathic pulmonary fibrosis based on syndrome differentiation: Study protocol of an exploratory trial.
    Yu XQ; Yang SG; Xie Y; Li JS
    J Integr Med; 2020 Mar; 18(2):163-168. PubMed ID: 31928920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).
    Maher TM; Kreuter M; Lederer DJ; Brown KK; Wuyts W; Verbruggen N; Stutvoet S; Fieuw A; Ford P; Abi-Saab W; Wijsenbeek M
    BMJ Open Respir Res; 2019; 6(1):e000422. PubMed ID: 31179008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opioids in patients with COPD and refractory dyspnea: literature review and design of a multicenter double blind study of low dosed morphine and fentanyl (MoreFoRCOPD).
    van Dijk M; Mooren KJM; van den Berg JK; van Beurden-Moeskops WJC; Heller-Baan R; de Hosson SM; Lam-Wong WY; Peters L; Pool K; Kerstjens HAM
    BMC Pulm Med; 2021 Sep; 21(1):289. PubMed ID: 34507574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF).
    Richeldi L; Azuma A; Cottin V; Kreuter M; Maher TM; Martinez FJ; Oldham JM; Valenzuela C; Gordat M; Liu Y; Stowasser S; Zoz DF; Wijsenbeek MS
    BMJ Open Respir Res; 2023 Aug; 10(1):. PubMed ID: 37597969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etiology and treatment of cough in idiopathic pulmonary fibrosis.
    Vigeland CL; Hughes AH; Horton MR
    Respir Med; 2017 Feb; 123():98-104. PubMed ID: 28137504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA
    Corte TJ; Lancaster L; Swigris JJ; Maher TM; Goldin JG; Palmer SM; Suda T; Ogura T; Minnich A; Zhan X; Tirucherai GS; Elpers B; Xiao H; Watanabe H; Smith RA; Charles ED; Fischer A
    BMJ Open Respir Res; 2021 Dec; 8(1):. PubMed ID: 34969771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.
    Abdulqawi R; Dockry R; Holt K; Layton G; McCarthy BG; Ford AP; Smith JA
    Lancet; 2015 Mar; 385(9974):1198-205. PubMed ID: 25467586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
    Maher TM; Stowasser S; Nishioka Y; White ES; Cottin V; Noth I; Selman M; Rohr KB; Michael A; Ittrich C; Diefenbach C; Jenkins RG;
    Lancet Respir Med; 2019 Sep; 7(9):771-779. PubMed ID: 31326319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment and Management of Cough in Idiopathic Pulmonary Fibrosis: A Narrative Review.
    Liu S; Ye X
    Lung; 2023 Dec; 201(6):531-544. PubMed ID: 37934241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.
    Behr J; Nathan SD; Harari S; Wuyts W; Kirchgaessler KU; Bengus M; Gilberg F; Wells AU
    Respir Med; 2018 May; 138():13-20. PubMed ID: 29724385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
    Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
    Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor.
    Maher TM; Simpson JK; Porter JC; Wilson FJ; Chan R; Eames R; Cui Y; Siederer S; Parry S; Kenny J; Slack RJ; Sahota J; Paul L; Saunders P; Molyneaux PL; Lukey PT; Rizzo G; Searle GE; Marshall RP; Saleem A; Kang'ombe AR; Fairman D; Fahy WA; Vahdati-Bolouri M
    Respir Res; 2020 Mar; 21(1):75. PubMed ID: 32216814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
    King TE; Brown KK; Raghu G; du Bois RM; Lynch DA; Martinez F; Valeyre D; Leconte I; Morganti A; Roux S; Behr J
    Am J Respir Crit Care Med; 2011 Jul; 184(1):92-9. PubMed ID: 21474646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study.
    Ryerson CJ; Camp PG; Eves ND; Schaeffer M; Syed N; Dhillon S; Jensen D; Maltais F; O'Donnell DE; Raghavan N; Roman M; Stickland MK; Assayag D; Bourbeau J; Dion G; Fell CD; Hambly N; Johannson KA; Kalluri M; Khalil N; Kolb M; Manganas H; Morán-Mendoza O; Provencher S; Ramesh W; Rolf JD; Wilcox PG; Guenette JA
    Ann Am Thorac Soc; 2016 Sep; 13(9):1640-7. PubMed ID: 27348402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of nintedanib in Japanese patients with early-stage idiopathic pulmonary fibrosis: a study protocol for an observational study.
    Sakamoto N; Hamada N; Okamoto M; Tobino K; Ichiyasu H; Ishii H; Ichikado K; Morimoto S; Hosogaya N; Mukae H
    BMJ Open; 2021 Jun; 11(6):e047249. PubMed ID: 34187824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of gabapentin for the treatment of refractory cough associated with interstitial lung disease: study protocol for a randomized, double-blind and placebo-controlled clinical trial.
    Gao R; Xu X; Wang S; Pu J; Shi C; Wen S; Zhu Y; Tang J; Wang X; Yu L
    Trials; 2022 Feb; 23(1):165. PubMed ID: 35189953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial.
    Wilson EC; Shulgina L; Cahn AP; Chilvers ER; Parfrey H; Clark AB; Twentyman OP; Wilson AM
    Pharmacoeconomics; 2014 Jan; 32(1):87-99. PubMed ID: 24307539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.